JP
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Literature - Publication Review
Biopolymers Codelivering Engineered T Cells and STING Agonists can Eliminate Heterogenous Tumors
Adoptive cell transfer using chimeric antigen receptor (CAR-T) cell therapy in which the patient’s T-cells are extracted, genetically modified, and transferred back into the patient with the aim that these altered cells can recognize and attack cancer cells has revolutionized cancer immunotherapy. Although very successful in treating hematological malignancies, CAR T therapy is more challenging in treating solid tumors.
Learn how researchers at the Fred Hutchinson Cancer Research Center and University of Washington used the IVIS® Spectrum non-invasive imaging system to evaluate the synergistic antitumor effect of co-delivery of CAR T cells and STING-agonists via biopolymer scaffolds in an orthotopic murine model of pancreatic cancer.
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions
Download Resource
Biopolymers Codelivering Engineered T Cells and STING Agonists can Eliminate Heterogenous Tumors